ArticleJournal of gastroenterology and hepatology2022
Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Article in Journal of gastroenterology and hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Guideline
- Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study.BMJ open gastroenterology · 2023Trial
- Candida Tropicalis Biofilm Formation Under Secondary Bile Salt Sodium Deoxycholate.Current microbiology · 2026Article
- Associations between maternal exposure to per- and polyfluoroalkyl substances and functional constipation in children at 3 and 4 years: the Japan Environment and Children's Study.Environmental health and preventive medicine · 2026Article
- Article
- Elobixibat Improves Stool/Gas Distribution and Fecal Bile Acids in Older Adults With Chronic Constipation.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Efficacy of elobixibat for elderly patients with chronic constipation in a clinic.World journal of gastrointestinal pharmacology and therapeutics · 2025Article
- Alterations in intestinal bile acid transport provide a therapeutic target in patients with post-bariatric hypoglycaemia.Nature metabolism · 2025Article
- Correlation of the intestinal flora and its metabolites with the colonic transport function in functional constipation.Frontiers in microbiology · 2025Article
- Patients with symptomatic uncomplicated diverticular disease have high fecal bile acid concentrations.Frontiers in medicine · 2025Article
- Article
- Gut Frailty: Its Concept and Pathogenesis.Digestion · 2024Review
- Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis.Hepatology international · 2023Article
- Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice.Frontiers in nutrition · 2023Article
- Gut microbiota: a new avenue to reveal pathological mechanisms of constipation.Applied microbiology and biotechnology · 2022Review
- Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.Journal of gastroenterology and hepatology · 2022Article
- [Advances in the Treatment of Refractory Pediatric Constipation].Acta gastroenterologica LatinoamericanaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND
aimElobixibat is a locally acting inhibitor of the ileal bile acid transporter. We compared bile acid metabolism between healthy subjects and patients with chronic constipation and assessed changes in the bile acid profile after elobixibat administration in the latter group.
methodsHealthy subjects (n = 10) and patients with chronic constipation (n = 19) were assessed as inpatients for 7 days, during which they received meals containing ~60 g/day of fat. Patients with chronic constipation remained as inpatients for a further 7 days for once-daily elobixibat administration. Assessments included concentrations of fecal and serum bile acids, serum 7α-hydroxy-4-cholesten-3-one (C4) and fibroblast growth factor 19, and bowel movements and constipation symptoms.
resultsFecal total and primary bile acids were significantly lower in patients with chronic constipation versus healthy subjects. Serum C4 and fibroblast growth factor 19 levels were comparable between groups. Elobixibat treatment increased fecal total and primary bile acids and decreased levels of fecal lithocholic acid and serum total as well as secondary bile acids in patients with chronic constipation. Bowel movements and other constipation-related symptoms were also improved by elobixibat to levels almost comparable with those of healthy subjects.
conclusionsDespite comparable C4 levels, patients with chronic constipation demonstrated decreased levels of fecal bile acids versus healthy subjects. Elobixibat treatment increased fecal bile acid excretion and reduced serum bile acid concentrations. The improvement of constipation after elobixibat treatment was associated with increased total bile acids, particularly primary bile acids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.